ACAD Stock Recent News
ACAD LATEST HEADLINES
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year's recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year. “Families affected by Rett syndro.
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.